<DOC>
	<DOCNO>NCT00005031</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient persistent recurrent refractory endometrial cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Persistent Recurrent , Refractory Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity 6-hydroxymethylacylfulvene patient persistent recurrent , refractory endometrial carcinoma . II . Determine nature degree toxicity treatment patient . OUTLINE : This multicenter study . Patients receive 6-hydroxymethylacylfulvene IV 5 minute day 1-4 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : Approximately 19-51 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm endometrial carcinoma refractory curative therapy establish treatment Clinically histologically confirm persistent recurrent disease Bidimensionally measurable disease ( ascites pleural effusion consider measurable ) Not eligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No clinically uncontrolled dysrhythmia sign ischemia per ECG No congestive heart failure require medication No uncontrolled hypertension Other : No significant active infection No prior concurrent malignancy within past 5 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy recover No 1 prior chemotherapy regimen allow ( either single combination cytotoxic drug therapy ) No prior 6hydroxymethylacylfulvene No prior chemotherapy malignancy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover No prior radiotherapy malignancy Surgery : At least 3 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>